Recent advances in genetics and treatment of hypertrophic cardiomyopathy

Area of Science:

• Cardiology
• Genetics
• Molecular Biology

Background:

• Hypertrophic cardiomyopathy (HCM) presents with diverse clinical outcomes, including sudden cardiac death and heart failure.
• Over 200 mutations in numerous genes are linked to HCM, indicating a strong genetic basis.
• Current medical treatments like beta-blockers and calcium channel blockers primarily manage symptoms without impacting mortality or disease progression.

Purpose of the Study:

• To review the current understanding of hypertrophic cardiomyopathy (HCM) pathogenesis and treatment options.
• To explore the potential of novel therapeutic strategies targeting molecular pathways involved in HCM.
• To highlight the need for comparative studies on existing interventions for HCM.

Main Methods:

• Review of existing literature on the molecular genetics of HCM.
• Analysis of findings from genetic animal models investigating therapeutic targets.
• Evaluation of current medical, surgical, and interventional treatment modalities for HCM.

Main Results:

• The genetic underpinnings of HCM are extensively identified, with numerous causative mutations known.
• Animal models suggest that targeting specific molecules can potentially reverse cardiac hypertrophy and fibrosis in HCM.
• Surgical myomectomy and ethanol septal ablation effectively alleviate left ventricular outflow tract obstruction.

Conclusions:

• While medical therapies offer symptomatic relief in HCM, they do not alter mortality or reverse the disease phenotype.
• Emerging evidence from animal studies supports the development of targeted molecular therapies for HCM.
• Randomized clinical trials are essential to compare the efficacy of medical management, ethanol septal ablation, and surgical myomectomy in HCM patients.